Safety of oral direct acting antiviral regimens for chronic hepatitis C in real life conditions

References

• Jimenez Galan R, Albacete Ramirez A, Monje Agudo P, et al. Nuevos fármacos en el abordaje terapéutico de la hepatitis C. New drugs in the treatment of chronic hepatitis C]. Farm Hosp. 2014;38(3):231–247. Spanish
   PubMedGoogle Scholar
• Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370(20):1889–1898.
   PubMed Web of Science ®Google Scholar
• Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370(16):1483–1493.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Kowdley KV, Coakley E, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370(17):1594–1603.
   PubMed Web of Science ®Google Scholar
• Leroy V, Angus P, Bronowicki JP, et al. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology. 2016;63(5):1430–1441.
   PubMed Web of Science ®Google Scholar
• Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–1765.
   PubMed Web of Science ®Google Scholar
• Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370(21):1983–1992.
   PubMed Web of Science ®Google Scholar
• Alqahtani SA, Afdhal N, Zeuzem S, et al. Safety and tolerability of ledipasvir/sofosbuvir with and without ribavirin in patients with chronic hepatitis C virus genotype 1 infection: analysis of phase III ION trials. Hepatology. 2015;62(1):25–30.
   PubMed Web of Science ®Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios. Viekirax technical information. [cited 2016 Aug 16]. Available from: http://www.aemps.es/cima/fichasTecnicas.do?metodo=buscar
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios. Harvoni technical information. [cited 2016 Aug 16]. Available from: http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=buscar
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios. Daklinza technical information. [cited 2016 Aug 16]. Available from: http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=buscar
   Google Scholar
• Agencia Española de Medicamentos y Productos Sanitarios. Olysio technical information. [cited 2016 Aug 16]. Available from: http://www.aemps.gob.es/cima/fichasTecnicas.do?metodo=buscar
   Google Scholar
• Renet S, Chaumais MC, Antonini T, et al. Extreme bradycardia after first doses of sofosbuvir and daclatasvir in patients receiving amiodarone: 2 cases including a rechallenge. Gastroenterology. 2015;149(6):1378–80.e1.
   PubMed Web of Science ®Google Scholar
• EMA Drug Safety Comunication. EMA recommends avoidance of certain hepatitis C medicines and amiodarone together. [cited 2016 Aug 17]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Press_release/2015/04/WC500186152.pdf
   Google Scholar
• Sección Farmacovigilancia Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Riesgo de descompensación e insuficiencia hepática tras la administración de Viekirax®. [cited 2016 Aug 22]. Available from: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2015/NI-MUH_FV_13-insuficiencia-hepatica-viekirax.htm
   Google Scholar
• Sección Farmacovigilancia Agencia Española de Medicamentos y Productos Sanitarios (AEMPS). Antivirales de Acción Directa en el tratamiento de la hepatitis C: evaluación del riesgo de reactivación de hepatitis B y recurrencia de carcinoma hepatocelular. [cited 2016 Dec 08]. Available from: https://www.aemps.gob.es/informa/notasInformativas/medicamentosUsoHumano/seguridad/2016/NI-MUH_FV_17-antivirales.htm
   Google Scholar
• Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol. 2013;59(3):434–441.
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. EASL Recommendations on treatment of hepatitis C 2015. J Hepatol. 2015;63(1):199–236.
   PubMed Web of Science ®Google Scholar
• Panel AIHG. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating adults infected with hepatitis C virus. Hepatology. 2015;62(3):932–954.
   PubMed Web of Science ®Google Scholar
• Ministerio de Sanidad, Servicio Sociales e Igualdad. Plan estratégico para el abordaje de la Hepatitis C en el Sistema Nacional de Salud: Ministerio de Sanidad, Servicio Sociales e Igualdad. [cited 2016 Jun 23]. Available from: http://www.msssi.gob.es/ciudadanos/enfLesiones/enfTransmisibles/docs/plan_estrategico_hepatitis_C.pdf
   Google Scholar
• Pang JX, Zimmer S, Niu S, et al. Liver stiffness by transient elastography predicts liver-related complications and mortality in patients with chronic liver disease. Plos One. 2014;9(4):e95776.
   PubMed Web of Science ®Google Scholar
• WHO. Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. In: Vitamin and Mineral Nutrition Information System. Geneva: World Health Organization; 2011 (WHO/NMH/NHD/MNM/11.1). [cited 2016 Dec 14]. Available from: http://www.who.int/vmnis/indicators/haemoglobin.pdf
   Google Scholar
• Flisiak R, Janczewska E, Wawrzynowicz-Syczewska M, et al. Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir +/- dasabuvir +/- ribavirin in hepatitis C: AMBER study. Aliment Pharmacol Ther. 2016;44(9):946–956.
   PubMed Web of Science ®Google Scholar
• Welzel TM, Petersen J, Herzer K, et al. Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort. Gut. 2016;65:1861–1870.
   PubMed Web of Science ®Google Scholar
• Saxena V, Nyberg L, Pauly M, et al. Safety and efficacy of simeprevir/sofosbuvir in hepatitis C-infected patients with compensated and decompensated cirrhosis. Hepatology. 2015;62(3):715–725.
   PubMed Web of Science ®Google Scholar
• Maan R, Van Tilborg M, Deterding K, et al. Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol. 2016;14(12):1821–30.e6.
   PubMed Web of Science ®Google Scholar
• Feld JJ, Moreno C, Trinh R, et al. Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks. J Hepatol. 2016;64(2):301–307.
   PubMed Web of Science ®Google Scholar
• Sulkowski MS, Vargas HE, Di Bisceglie AM, et al. Effectiveness of simeprevir plus sofosbuvir, with or without ribavirin, in real-world patients with HCV genotype 1 infection. Gastroenterology. 2016;150(2):419–429.
   PubMed Web of Science ®Google Scholar
• Eletreby R, Elakel W, Said M. et al. Real life Egyptian experience of efficacy and safety of Simeprevir/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int. 2016 Oct:6. DOI:10.1111/liv.13266
   Web of Science ®Google Scholar
• Gower E, Estes C, Blach S, et al. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45–57.
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Park H, Gordon SC, et al. Real-world outcomes of ledipasvir/sofosbuvir in treatment-naive patients with hepatitis C. Am J Manag Care. 2016;22(6 Spec No.):Sp205–11.
   PubMed Web of Science ®Google Scholar
• Rodriguez-Torres M. Sofosbuvir (GS-7977), a pan-genotype, direct-acting antiviral for hepatitis C virus infection. Expert Rev Anti Infect Ther. 2013;11(12):1269–1279.
   PubMed Web of Science ®Google Scholar
• You DM, Pockros PJ. Simeprevir for the treatment of chronic hepatitis C. Expert Opin Pharmacother. 2013;14(18):2581–2589.
   PubMed Web of Science ®Google Scholar
• Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149(3):649–659.
   PubMed Web of Science ®Google Scholar
• Reig M, Marino Z, Perello C, et al. Unexpected high rate of early tumor recurrence in patients with HCV-related HCC undergoing interferon-free therapy. J Hepatol. 2016;65(4):719–726.
   PubMed Web of Science ®Google Scholar
• Conti F, Buonfiglioli F, Scuteri A, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with direct-acting antivirals. J Hepatol. 2016;65(4):727–733.
   PubMed Web of Science ®Google Scholar
• EMA Drug Safety Communication. Direct-acting antivirals for hepatitis C: EMA confirms recommendation to screen for hepatitis B. [cited 2017 Mar 07]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/Direct-acting_antivirals_for_hepatitis_C_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500218179.pdf
   Google Scholar
• Forns X, Lawitz E, Zeuzem S, et al. Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial. Gastroenterology. 2014;146(7):1669–79.e3.
   PubMed Web of Science ®Google Scholar
• Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014;384(9941):403–413.
   PubMed Web of Science ®Google Scholar
• Baba H, Tajiri K, Nagata K, et al. Hyperbilirubinemia without Transaminitis during Combined Therapy with Daclatasvir and Asunaprevir. Case Rep Gastroenterol. 2016;10(2):352–359.
   PubMedGoogle Scholar
• Huisman MT, Snoeys J, Monbaliu J, et al. In vitro studies investigating the mechanism of interaction between TMC435 and hepatic transporters. Hepatology. 2010;52(Suppl. 1):461A–2A.
   Google Scholar
• Tahata Y, Hiramatsu N, Oze T, et al. The impact of an inosine triphosphate pyrophosphatase genotype on bilirubin increase in chronic hepatitis C patients treated with simeprevir, pegylated interferon plus ribavirin. J Gastroenterol. 2016;51(3):252–259.
   PubMed Web of Science ®Google Scholar
• Ciesek S, Proske V, Otto B, et al. Efficacy and safety of sofosbuvir/ledipasvir for the treatment of patients with hepatitis C virus re-infection after liver transplantation. Transpl Infect Dis. 2016;18(3):326–332.
   PubMed Web of Science ®Google Scholar
• D’Ambrosio R, Colombo M. Safety of direct antiviral agents in real life. Dig Liver Dis. 2013;45(Suppl 5):S363–6.
   PubMedGoogle Scholar
• Hundemer GL, Sise ME, Wisocky J, et al. Use of sofosbuvir-based direct-acting antiviral therapy for hepatitis C viral infection in patients with severe renal insufficiency. Infect Dis (Lond). 2015;47(12):924–929.
   PubMed Web of Science ®Google Scholar
• Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C-infected patients with impaired renal function. Liver Int. 2016;36(6):807–816.
   PubMed Web of Science ®Google Scholar
• Aldámiz-Echevarría T, Diez C, Miralles P, et al. Increase in 10-Year framingham cardiovascular risk following HCV eradication with DAA-based therapy in HIV/HCV-coinfected patients [abstract]. In: AASLD abstract supplement: the liver meeting; 2016 nov 11-15; Boston, USA. Hepatology. 2016;64(1 Suppl):S1009A.
   Google Scholar
• Vermehren J, Peiffer KH, Welsch C, et al. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection. Aliment Pharmacol Ther. 2016;44(8):856–865.
   PubMed Web of Science ®Google Scholar
• Conti F, Brillanti S, Buonfiglioli F. et al. Safety and efficacy of direct-acting antivirals for the treatment of chronic hepatitis C in a real-world population aged 65 years and older. J Viral Hepat. 2016. doi:10.1111/jvh.12663. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar